Business
Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution
VANCOUVER, British Columbia & GRAPEVINE, Texas, January 07, 2026--Alpha Cognition, Inc. (the "Company", "we", "us" and "ours") (NASDAQ: ACOG), a commercial-stage neuroscience company focused on advancing treatments for cognitive and neuropsychiatric disorders, today announced a corporate update outlining strategic priorities for 2026 and summarizing key accomplishments achieved in 2025.
About this update from Alpha Cognition Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1402,"height":504,"url":"https://media.zenfs.com/en/business-wire.com/b4f31c3a06488dc39b17f9e4adb0700e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eSSW.LzIAylpOukcJwxvEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b4f31c3a06488dc39b17f9e4adb0700e","width":960,"height":345},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xXvs0DbBryMto60mYnUiJw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b4f31c3a06488dc39b17f9e4adb0700e","width":1200,"height":431}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"ZUNVEYL prescriber base expected to expand to approximately 2,000 prescribing healthcare providers, and an increase in nursing home penetration","length":143,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Company expects to complete and/or initiate three studies in 2026 supporting ZUNVEYL’s impact in Alzheimer’s disease patients in long-term care settings","length":152,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"ZUNVEYL commercialization efforts expected to support operating profitability in 2027","length":85,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":380,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia & GRAPEVINE, Texas, January 07, 2026--(BUSINESS WIRE)--Alpha Cognition, Inc. (the "Company", "we", "us" and "ours") (NASDAQ: ACOG), a commercial-stage neuroscience company focused on advancing treatments for cognitive and neuropsychiatric disorders, today announced a corporate update outlining strategic priorities for 2026 and summarizing key accomplishments achieved in 2025.","length":450,"tagName":"p"},{"type":"text","content":"Management Commentary, Michael McFadden, Chief Executive Officer","length":64,"tagName":"p"},{"type":"text","content":""We are pleased with the transition from the initial launch to a phase of commercial expansion of ZUNVEYL in 2026.","length":119,"tagName":"p"},{"type":"text","content":"Our efforts in the new year focus on achieving scale of ZUNVEYL’s expansion strategy – with a keen focus on addressing th...